Prostate Cancer Treatment with Actinium-225 PSMA (program ID: 447971)
University Hospital Tuebingen
Christian la FougèreSpecialized in: nuclear medicine, clinical imaging diagnostics
Department of Nuclear Medicine and Clinical Imaging Diagnostics
- Initial presentation in the clinic
- clinical history taking
- general physical examination
- laboratory tests:
- complete blood count
- biochemical analysis of blood
- TSH-basal, fT3, fT4
- PSA blood level
- tests for urogenital infections
- indicators of inflammation
- indicators of blood coagulation
- ultrasound scan of the urogenital system
- renal scintigraphy
- PSMA PET-CT
- PSMA treatment with Actinium-225
- full body scintigraphy after 24 hours
- full body scintigraphy after 48 hours
- symptomatic treatment
- cost of essential medicines
- nursing services
- elaboration of further recommendations
- stay in the hospital with full board
- accommodation in 2-bedded room
How program is carried out
During the first visit, the doctor will carry out a general physical examination and go through the results of previous laboratory and instrumental tests. After that, you will undergo the necessary additional tests such as the assessment of liver and kidney function, scintigraphy of the skeleton and salivary glands, PSMA PET / CT. This will allow the doctor to assess how effective PSMA therapy with Actinium-225 will be and how well you will tolerate it. Also, the doctor will calculate your individual dosage of the radionuclide.
PSMA therapy with Actinium-225 is carried out via intravenous administration of a solution with the radioactive isotope Actinium-225. The solution is injected through a catheter. This is a short procedure, as the infusion usually takes no more than 20 minutes.
During the procedure, you will need to apply cooling bags to the salivary glands, as Actinium-225 partially accumulates in the salivary glands, affecting their function and causing dry mouth. You will also receive intravenous saline solutions to protect your kidneys.
After the infusion of Actinium-225, you will stay in a specially equipped (radiation-shielded) ward for 48 hours. The drug is quickly excreted by the kidneys, and after 48 hours you will no longer be dangerous to others. During these 48 hours, you can read, use a mobile phone, tablet or computer – all these devices will not be a source of radiation in the future.
Follow-up examinations include whole-body scintigraphy or computed tomography in 24 hours and 48 hours after the procedure. Based on the results of the examination, the doctor will determine whether one procedure is enough for you, or whether you will need to visit the hospital again. As a rule, 1-2 procedures are required for achieving a stable positive result. Procedures are carried out with an interval of 8 weeks.
- Medical records
- PSA blood test
- MRI/CT scan (not older than 3 months)
- Bone scintigraphy (if available)
- Biopsy results (if available)
You may also book
About the department
The Department of Nuclear Medicine and Clinical Imaging Diagnostics at the University Hospital Tuebingen offers the full range of radioisotope diagnostics and treatment of various diseases. The department is headed by Prof. Dr. med. Christian la Fougère.
Both classical diagnostic methods, for example, scintigraphy, SPECT and innovative hybrid techniques, for example, PET-CT, PET-MRT, SPECT-CT are available in the department, which allow to detect metabolic changes at the early stages of various diseases, as well as their localization in the human body. In addition, the department's doctors specialize in radiotherapy for the treatment of oncopathologies.
The diagnostic range of the department covers:
- Osteoscintigraphy (skeleton scintigraphy)
- Thyroid scintigraphy
- Preoperative marking of the sentinel lymph nodes
- Renal scintigraphy
- Scintigraphy in inflammatory processes
- Ventilation/perfusion lung scintigraphy
- Myocardial scintigraphy
- Brain scintigraphy (DaTSCAN)
- Liver scintigraphy
- Parathyroid scintigraphy
- Scintigraphy for the determination of the degree of gastric emptying
- Scintigraphy for the determination of the hemorrhage source
- Thyroid diagnostics (within the specialized outpatient clinic)
- Ultrasound examinations
- Fine-needle aspiration biopsy
- Other diagnostic methods
The therapeutic options of the department:
- Radiation therapy for the treatment of benign and malignant diseases of the thyroid gland
- Selective internal radiation therapy for the treatment of liver tumors and metastases
- Peptide receptor radionuclide therapy for the treatment of malignant neuroendocrine tumors
- Lu-177 PSMA radionuclide therapy for the treatment of prostate cancer and its metastases
- Therapy for the treatment of prostate cancer and metastasis
- MIBG therapy for the treatment of neuroendocrine tumors
- Samarium radiation therapy for the treatment of certain forms of bone cancer
- Other types of radiation therapy
- 2017 and up to now, Deputy Managing Director, Department of Radiology, University Hospital Tuebingen.
- 2013 and up to now, Full Professor and Director, Department of Nuclear Medicine and Clinical Imaging Diagnostics, University Hospital Tuebingen.
- 2010 Associate Professor of Nuclear Medicine, Ludwig Maximilian University of Munich.
- 2009 - 2013 Chief of the Section of Neurological and Neuro-Oncological Imaging, Department of Nuclear Medicine, Ludwig Maximilian University of Munich.
- 2008 - 2009 Research Fellow, Brain Imaging Centre, Montréal Neurological Institute, McGill-University, Canada.
- 2003 Doctor of Medicine, Ludwig Maximilian University of Munich.
- 2002 - 2008 Resident, Department of Nuclear Medicine, Ludwig Maximilian University of Munich.
- 2002 German Medical License, Ludwig Maximilian University of Munich.
- 2001 - 2002 Elective, Department of Internal Medicine, Hôpital Européen Georges Pompidou, University of Paris, and at the Departments of Surgery and Radiology, Ludwig Maximilian University of Munich.
Scholarships, Awards and Administrative Functions
- 2018 Executive Board Member, German Society of Nuclear Medicine (DGN).
- 2017 Program Chair, German Nuclear Imaging Congress.
- 2016 Spokesman, Committee on Multi-Center-Trials of the German Society of Nuclear Medicine (DGN).
- 2015 Board Member, Comprehensive Cancer Center Tuebingen-Stuttgart.
- 2015 Member, Editorial Board of the Nuclear Medicine Journal.
- 2015 Member, Editorial Board, Der Nukelarmediziner.
- 2011 Committee Member, Neuro-Nuclear Medicine Board of the German Society of Nuclear Medicine.
- 2008 - 2009 Scholarship from German Research Foundation (DFG).
- 2008 Scholarship from the Bavarian Research Alliance (Bayerische Forschungsallianz).
- 2005 Scholarship from Ludwig Maximilian University of Munich.
Photo of the doctor: (c) Universitätsklinikum Tübingen
Accommodation in hospital
- Program [Description]
Prostate Cancer Treatment with Actinium-225 PSMA
- Hospital: University Hospital Tuebingen
- access_time Duration:
There are 26 metastatic prostate cancer treatment hospitals on Booking Health websiteShow all clinics